Please use this identifier to cite or link to this item:
|Title:||Where has all the botox gone? (How) will we ever learn... Using monoclonal antibodies to track botulinum toxin||Authors:||Lim, E.C.-H.
|Issue Date:||2006||Citation:||Lim, E.C.-H., Oh, V.M.S., Ong, B.K.C., Chow, A.W.L., Seet, R.C.S. (2006). Where has all the botox gone? (How) will we ever learn... Using monoclonal antibodies to track botulinum toxin. Medical Hypotheses 67 (3) : 440-446. ScholarBank@NUS Repository. https://doi.org/10.1016/j.mehy.2006.03.014||Abstract:||Botulinum toxin (BTX) is an important therapeutic tool in the treatment of overactive skeletal and smooth muscles, as well as hypersecretory and painful disorders. Despite advances in our understanding of how BTX works, much remains to be elucidated, such as how BTX ameliorates pain, how it produces weakness remote from the site of injection and the fate of the heavy and light chain components of the BTX molecule following endocytosis into the presynaptic membrane. BTX, conjugated to radionuclides, allows investigators to track the molecule both in vitro and in vivo. However, altering the BTX molecule may cause structural changes or pharmacokinetic and pharmacodynamic alterations, and disrupt its normal action. We propose instead to bind the biomarkers (appropriate dyes, radionuclides or MRI contrast agents) to monoclonal antibodies directed against either heavy or light chain components of BTX, thus allowing administration of native (i.e. unaltered) BTX. © 2006 Elsevier Ltd. All rights reserved.||Source Title:||Medical Hypotheses||URI:||http://scholarbank.nus.edu.sg/handle/10635/26723||ISSN:||03069877||DOI:||10.1016/j.mehy.2006.03.014|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 18, 2019
WEB OF SCIENCETM
checked on Jun 11, 2019
checked on May 25, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.